Healthcare Triangle, Inc. (HCTI)
NASDAQ: HCTI · Real-Time Price · USD
2.190
-0.110 (-4.78%)
Dec 5, 2025, 4:00 PM EST - Market closed
Healthcare Triangle Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Healthcare Triangle in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Healthcare Triangle.
Recommendation Trends
| Rating | Jul '22 | Aug '22 | Sep '22 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| EF Hutton | EF Hutton | Strong Buy Maintains $9,960 → $4,980 | Strong Buy | Maintains | $9,960 → $4,980 | +227,297.26% | Sep 28, 2022 |
| EF Hutton | EF Hutton | Strong Buy Initiates $9,960 | Strong Buy | Initiates | $9,960 | +454,694.52% | Mar 14, 2022 |
Financial Forecast
Revenue This Year
17.19M
from 11.70M
Increased by 47.01%
Revenue Next Year
24.91M
from 17.19M
Increased by 44.88%
EPS This Year
-1.87
from -281.58
EPS Next Year
-0.54
from -1.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 17.7M | 25.6M | ||
| Avg | 17.2M | 24.9M | ||
| Low | 16.5M | 23.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 51.3% | 49.1% | ||
| Avg | 47.0% | 44.9% | ||
| Low | 41.2% | 39.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -1.92 | -0.56 | ||
| Avg | -1.87 | -0.54 | ||
| Low | -1.79 | -0.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.